Latest Breaking News On - He immu se0005003654 - Page 1 : comparemela.com

Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company has agreed with Negma Group Ltd to redeem the remainder of the first. | April 6, 2023

Mario brkuljCorey davisErik mantingLifesci advisorsNegma group ltdValency communicationsVan herk investmentsAbuse regulationSci advisorsMendus ab publ stock exchangePress releaseHe immu se0005003654